“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Wednesday, August 27, 2025

Aerie Pharmaceuticals


Aerie Pharmaceuticals — A to Z Product Catalog


Marketed Products (now under Alcon)

  • Rhopressa® (netarsudil 0.02% ophthalmic solution)
    • Generic: Netarsudil (Rho kinase inhibitor)
    • Indication: Reduction of elevated intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension
    • Dose/Form: Once-daily ophthalmic eye drop

  • Rocklatan® (netarsudil 0.02% + latanoprost 0.005% ophthalmic solution)
    • Generic: Combination of netarsudil (Rho kinase inhibitor) + latanoprost (prostaglandin analogue)
    • Indication: Reduction of elevated IOP in open-angle glaucoma or ocular hypertension
    • Dose/Form: Once-daily fixed-dose combination ophthalmic eye drop

Late-Stage Investigational Product

  • AR-15512
    • Generic: Cold thermoreceptor modulator (topical)
    • Indication: Dry eye disease
    • Dose/Form: Ophthalmic formulation; administered twice daily; Phase 3 clinical-stage

Earlier-Stage Pipeline Candidates

  • AR-13503
    • Type: PKC × ROCK inhibitor
    • Indication: Diabetic macular edema (and explored for wet age-related macular degeneration)
    • Dose/Form: Investigational

  • AR-6121
    • Type: ROCK inhibitor
    • Indication: Post-procedural ocular inflammation
    • Dose/Form: Investigational, preclinical stage


on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)